World First Male Contraceptive Enters Clinical Trials
- Normal Liver Cells Found to Promote Cancer Metastasis to the Liver
- Nearly 80% Complete Remission: Breakthrough in ADC Anti-Tumor Treatment
- Vaccination Against Common Diseases May Prevent Dementia!
- New Alzheimer’s Disease (AD) Diagnosis and Staging Criteria
- Breakthrough in Alzheimer’s Disease: New Nasal Spray Halts Cognitive Decline by Targeting Toxic Protein
- Can the Tap Water at the Paris Olympics be Drunk Directly?
World First Male Contraceptive Enters Clinical Trials
- Should China be held legally responsible for the US’s $18 trillion COVID losses?
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
World First Male Contraceptive Enters Clinical Trials
The world’s first male contraceptive is on the horizon, as it has officially entered clinical trials.
According to the University of Minnesota, a male contraceptive named YCT-529, developed by YourChoice Therapeutics, has commenced its Phase 1 clinical trials in the United Kingdom this week.
The drug’s tolerance, safety, pharmacokinetics, and efficacy will be evaluated in a cohort of 16 male participants. This marks the first non-hormonal male contraceptive to undergo clinical trials globally.
Historically, male contraceptives in clinical trials have been hormonal, exhibiting limited effectiveness and severe side effects.
Over the past few decades, from birth control pills to patches and intrauterine devices, women have borne the majority of the contraceptive burden.
Male contraceptive options have primarily included condom usage and vasectomy, but the irreversible nature of vasectomy has led to lower acceptance among men.
YCT-529, a collaboration between Professor Gunda Georg of the University of Minnesota and YourChoice Therapeutics, is a retinoic acid receptor inhibitor that prevents sperm formation by blocking the acquisition of vitamin A.
World First Male Contraceptive Enters Clinical Trials
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.